Pharmacokinetics, efficacy, and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)

被引：1
|
作者：
Yu, H. A. [1 ]
Cantero, F. [2 ]
Kim, B. [3 ]
Lee, M. [4 ]
Wu, E. [5 ]
Sternberg, D. W. [6 ]
Janne, P. A. [7 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Med Oncol, 1275 York Ave, New York, NY 10021 USA
[2] Daiichi Sankyo Inc, Oncol Clin Dev, Basking Ridge, NJ USA
[3] Daiichi Sankyo Inc, Clin Sci, Basking Ridge, NJ USA
[4] Daiichi Sankyo Inc, Quantitat Clin Pharmacol, Basking Ridge, NJ USA
[5] Daiichi Sankyo Inc, Biostat, Basking Ridge, NJ USA
[6] Daiichi Sankyo Inc, Oncol Clin Dev, Basking Ridge, NJ USA
[7] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1313
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1190TiP
引用
收藏
页码：S1092 / S1093
页数：2
相关论文
共 50 条
  • [41] Depression and Inflammation in Patients with EGFR-Mutated Non-Small Cell Lung Cancer
    Cardona, A.
    Arrieta, O.
    Rojas, L.
    Zatarain-Barron, Z.
    Ricaurte, L.
    Ruiz-Patino, A.
    Martin, C.
    Carranza, H.
    Vargas, C.
    Otero, J.
    Corrales, L.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S871 - S871
  • [42] NEUROLOGICAL EVOLUTION OF A PATIENT WITH EGFR-MUTATED NON-SMALL CELL LUNG CANCER
    Ianza, A.
    Dicorato, A.
    Guglielmi, A.
    Orlando, V.
    Furlanis, G.
    Curro, F.
    CHEST, 2022, 161 (06) : 333A - 333A
  • [43] Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer
    Mambetsariev, Isa
    Arvanitis, Leonidas
    Fricke, Jeremy
    Pharaon, Rebecca
    Baroz, Angel R.
    Afkhami, Michelle
    Koczywas, Marianna
    Massarelli, Erminia
    Salgia, Ravi
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (05)
  • [44] RICTOR signaling modulates the activity of EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutated non-small cell lung cancer (NSCLC)
    Fan, Ni
    Zou, Yiyu
    Halmos, Balazs
    Perez-Soler, Roman
    Cheng, Haiying
    CANCER RESEARCH, 2019, 79 (13)
  • [45] Pooled safety analysis of EGFR-TKI therapy in patients with EGFR-mutated non-small cell lung cancer.
    Takada, Masayuki
    Okamoto, Isamu
    Nakagawa, Kazuhiko
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [46] A Delphi Consensus on TKI Sequencing in Treating Advanced EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)
    Wehler, T.
    Hirsh, V.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1043 - S1043
  • [47] Kinase Fusions as Recurrent Mechanisms of Acquired Resistance in EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)
    Ou, S.
    Klempner, S.
    Creelan, B.
    Hsieh, W. S.
    Costin, D.
    Stephens, P. J.
    Ross, J.
    Miller, V.
    Ali, S.
    Schrock, A.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1848 - S1848
  • [48] A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives
    Russo, Alessandro
    Franchina, Tindara
    Ricciardi, Giuseppina Rosaria Rita
    Picone, Antonio
    Ferraro, Giuseppa
    Zanghi, Mariangela
    Toscano, Giuseppe
    Giordano, Antonio
    Adamo, Vincenzo
    ONCOTARGET, 2015, 6 (29) : 26814 - 26825
  • [49] Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC)
    Janne, Pasi A.
    Ramalingam, Suresh S.
    Yang, James Chih-Hsin
    Ahn, Myung-Ju
    Kim, Dong-Wan
    Kim, Sang-We
    Planchard, David
    Ohe, Yuichiro
    Felip, Enriqueta
    Watkins, Claire
    Cantarini, Mireiille
    Ghiorghiu, Serban
    Ranson, Malcolm
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [50] Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study
    Nio, Yuta
    Ishida, Hiroo
    Matsumoto, Natsumi
    Kusumoto, Sojiro
    Kubota, Yutaro
    Tsunoda, Takuya
    Sasaki, Yasutsuna
    Fujita, Ken-ichi
    BMC PULMONARY MEDICINE, 2022, 22 (01)
12345